Login
Navigate Fool.com
Will GERN beat
the market?

Geron Corp (NASDAQ: GERN)

Community Rating: 2 Stars: Unattractive

2.42 -0.11 (-4.35%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.51
Previous Close $2.53
Daily Range $2.40 - $2.53
52-Week Range $1.27 - $7.79
Market Cap $379.8M
P/E Ratio -9.37
Dividend (Yield) $0.00 (0.0%)
Volume 2,495,536
Average Daily Volume 5,838,865
Current FY EPS -$0.25

How do you think GERN
will perform against the market?

Top GERN Bull/Bear Pitches

 

fatmoneyrz (< 20)
Submitted October 17, 2013

I've got a mysterious vibe about GERN. When I was walking the city streets very early this morning a fortune teller on a small side street drew me in and wanted to read my palms. While doing so I lo … More

1 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted August 16, 2013

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate does … More

1 Replies Reply Report this Post

News & Commentary

3 Longtime Losers About to See Green?

These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?

Better Buy: Dynavax Technologies Corp. vs. Geron Corp.

Dynavax Technologies Corp. and Geron Corp. have pending catalysts that could cause their shares to double from current levels. Here's a Foolish look at which company offers the better risk-to-reward profile.

Will Investors Profit from Geron's Road to Recovery?

Geron gets a clinical hold released, but is still a ways away from competing with Incyte's Jakafi.

5 Stocks Under $10 Worth Buying

A small-priced stock can do big things if you can stomach the risk.

3 Stocks That Soared Stupendously This Week

2 of this week's biggest health-care winners scored triple-digit gains with another jumping over 40%. Here's how they did it.

This Week in Biotech: Actions Speak Louder Than Words

Regulatory actions provided the impetus to big moves for these five biotech stocks.

Is It Time to Buy Geron?

Geron had great news this week. Time to buy?

Why Geron, Restoration Hardware, and ImmunoGen Are Today's 3 Best Stocks

The S&P 500 suffers its worst loss in weeks following disappointing economic data, while Geron, Restoration Hardware, and ImmunoGen give investors a reason to smile.

Why Geron Corporation Shares Skyrocketed

Geron shares soar after the FDA gives the company some "partially" positive news.

US Futures Point to Lower Open as Data Disappoint; Global Growth Forecast Cut

See More GERN News...

Sector

Healthcare

Industry

Drugs

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website: http://www.geron.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks